WallStreetZenWallStreetZen

NASDAQ: CPIX
Cumberland Pharmaceuticals Inc Earnings & Revenue

OverviewForecastEarnings
DividendOwnership

CPIX past revenue growth

How has CPIX's revenue growth performed historically?
Company
16.75%
Industry
257.72%
Market
21.91%
CPIX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Industry Performance
CPIX's revenue has grown slower... subscribe to Premium to read more.
Revenue Growth vs Market Performance
CPIX's revenue growth is accelerating... subscribe to Premium to read more.
Accelerating Revenue Growth Performance

CPIX earnings and revenue history

Current Revenue
$42.0M
Current Earnings
-$5.6M
Current Profit Margin
-13.3%

CPIX Return on Equity

Current Company
-14.3%
Current Industry
16.8%
Current Market
188%
CPIX's Return on Equity (-14.3%)... subscribe to Premium to read more.
High Return on Equity Performance

Be the first to know when CPIX announces earnings.

CPIX Return on Assets

Current Company
-6%
Current Industry
4.7%
CPIX is generating lower Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

CPIX Return on Capital Employed

Current Company
-7.64%
Current Industry
10.8%
CPIX's ability to generate Return... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

CPIX vs Pharmaceutical Stocks

TickerRevenueEBITDAEarningsY/Y RevenueY/Y Earnings
CPIX$42.01M$412.72k-$5.57M+0.41%N/A
NLTX$0.00-$54.95M-$57.56M-100.00%N/A
DERM$75.22M-$23.71M-$40.74M+26.76%N/A
SLDB$11.25M-$86.81M-$89.44M+7.47%N/A
CRDL$0.00-$21.50M-$21.66M-100.00%N/A
View Top Pharmaceutical Stocks

CPIX earnings dates

Next earnings date
May 8, 2023

Cumberland Pharmaceuticals Earnings & Revenue FAQ

What were CPIX's earnings last quarter?

On Invalid Date, Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 2022 earnings per share (EPS) of -$0.17, up 34.62% year over year. Total Cumberland Pharmaceuticals earnings for the quarter were -$2.44 million. In the same quarter last year, Cumberland Pharmaceuticals's earnings per share (EPS) was -$0.26.

If you're new to stock investing, here's how to buy Cumberland Pharmaceuticals stock.

What was CPIX's earnings growth in the past year?

As of Q1 2023, Cumberland Pharmaceuticals's earnings has grown year over year. Cumberland Pharmaceuticals's earnings in the past year totalled -$5.57 million.

What is CPIX's earnings date?

Cumberland Pharmaceuticals's earnings date is Invalid Date. Add CPIX to your watchlist to be reminded of CPIX's next earnings announcement.

What was CPIX's revenue last quarter?

On Invalid Date, Cumberland Pharmaceuticals (NASDAQ: CPIX) reported Q4 2022 revenue of $9.12 million up 9.66% year over year. In the same quarter last year, Cumberland Pharmaceuticals's revenue was $8.32 million.

What was CPIX's revenue growth in the past year?

As of Q1 2023, Cumberland Pharmaceuticals's revenue has grown 16.75% year over year. This is 240.97 percentage points lower than the US Drug Manufacturers - Specialty & Generic industry revenue growth rate of 257.72%. Cumberland Pharmaceuticals's revenue in the past year totalled $42.01 million.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.